See more : Brookfield Finance Inc. 4.50% P (BAMI) Income Statement Analysis – Financial Results
Complete financial analysis of Itamar Medical Ltd. (ITMR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Itamar Medical Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Inspira Technologies Oxy B.H.N. Ltd. (IINNW) Income Statement Analysis – Financial Results
- Nuveen New York Select Tax-Free Income Portfolio (NXN) Income Statement Analysis – Financial Results
- Fresh2 Group Limited (FRES) Income Statement Analysis – Financial Results
- create restaurants holdings inc. (3387.T) Income Statement Analysis – Financial Results
- Tingo Group, Inc. (TIO) Income Statement Analysis – Financial Results
Itamar Medical Ltd. (ITMR)
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.03M | 31.26M | 24.19M | 20.70M | 18.44M | 16.81M | 16.39M | 13.34M | 13.43M |
| Cost of Revenue | 12.32M | 6.98M | 5.73M | 5.00M | 4.98M | 4.40M | 4.80M | 4.26M | 3.80M |
| Gross Profit | 28.71M | 24.27M | 18.46M | 15.70M | 13.46M | 12.41M | 11.59M | 9.08M | 9.62M |
| Gross Profit Ratio | 69.97% | 77.66% | 76.33% | 75.84% | 73.00% | 73.81% | 70.72% | 68.07% | 71.68% |
| Research & Development | 6.00M | 4.52M | 3.64M | 4.13M | 3.23M | 2.83M | 2.02M | 1.89M | 1.69M |
| General & Administrative | 8.50M | 6.35M | 5.25M | 5.28M | 5.36M | 4.30M | 4.63M | 4.88M | 2.55M |
| Selling & Marketing | 24.55M | 18.29M | 12.70M | 12.14M | 14.04M | 10.68M | 8.44M | 7.40M | 5.69M |
| SG&A | 33.05M | 24.65M | 17.95M | 17.42M | 19.40M | 14.98M | 13.07M | 12.28M | 8.23M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 849.00K | 52.00K | 113.00K | 117.00K | 217.00K |
| Operating Expenses | 39.06M | 29.17M | 21.58M | 21.55M | 23.47M | 17.87M | 15.20M | 14.29M | 10.14M |
| Cost & Expenses | 51.38M | 36.15M | 27.31M | 26.55M | 28.45M | 22.27M | 20.00M | 18.54M | 13.94M |
| Interest Income | 713.00K | 454.00K | 93.00K | 1.39M | 547.00K | 176.00K | -571.00K | 714.00K | 121.00K |
| Interest Expense | 562.00K | 284.00K | 794.00K | 4.43M | 4.61M | 4.19M | 2.51M | 4.83M | 2.12M |
| Depreciation & Amortization | 1.82M | 1.29M | 481.00K | 509.00K | 434.00K | 367.00K | 324.00K | 400.00K | 330.00K |
| EBITDA | -8.43M | -3.66M | -330.00K | -280.00K | -9.23M | 2.44M | -313.00K | -7.73M | 2.76M |
| EBITDA Ratio | -20.55% | -11.71% | -1.36% | -1.35% | -50.04% | 14.53% | -1.91% | -57.95% | 20.57% |
| Operating Income | -10.34M | -4.89M | -3.12M | -5.85M | -10.01M | -5.46M | -3.61M | -5.21M | -515.00K |
| Operating Income Ratio | -25.21% | -15.66% | -12.90% | -28.25% | -54.30% | -32.48% | -22.02% | -39.04% | -3.84% |
| Total Other Income/Expenses | -468.00K | -337.00K | 1.52M | 632.00K | -4.26M | 3.35M | 458.00K | -7.76M | 831.00K |
| Income Before Tax | -10.81M | -5.23M | -1.61M | -5.22M | -14.27M | -2.11M | -3.15M | -12.96M | 316.00K |
| Income Before Tax Ratio | -26.35% | -16.73% | -6.64% | -25.20% | -77.40% | -12.57% | -19.23% | -97.20% | 2.35% |
| Income Tax Expense | 127.00K | 37.00K | 124.00K | 85.00K | 131.00K | 135.00K | 124.00K | -44.00K | -201.00K |
| Net Income | -10.94M | -5.27M | -1.73M | -5.30M | -14.40M | -2.25M | -3.28M | -12.92M | 517.00K |
| Net Income Ratio | -26.66% | -16.85% | -7.15% | -25.61% | -78.11% | -13.37% | -19.99% | -96.87% | 3.85% |
| EPS | -0.79 | -0.46 | -0.17 | -0.60 | -1.65 | -0.35 | -0.56 | -2.82 | 0.03 |
| EPS Diluted | -0.79 | -0.46 | -0.17 | -0.52 | -1.65 | -0.29 | -0.46 | -2.82 | 0.03 |
| Weighted Avg Shares Out | 13.85M | 11.54M | 10.13M | 8.80M | 8.75M | 6.39M | 5.83M | 4.58M | 16.42M |
| Weighted Avg Shares Out (Dil) | 13.85M | 11.54M | 10.13M | 10.13M | 8.75M | 7.73M | 7.15M | 4.58M | 16.42M |
Itamar Medical Announces Closing of Public Offering of American Depositary Shares and Full Exercise of the Underwriters' Option to Purchase Additional ADSs
CAESAREA, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of...
Itamar Medical Announces Pricing of Public Offering of American Depositary Shares
CAESAREA, Israel, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of...
CORRECTION – Itamar Medical Announces Proposed Offering of American Depositary Shares
CAESAREA, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, February 4th by Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), please note that the contact information was incorrect. The corrected release follows:
Itamar Medical Announces Proposed Offering of American Depositary Shares
CAESAREA, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of...
Itamar Medical Appoints Scott P. Serota to its Board of Directors
CAESAREA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the...
How Itamar Medical Stock Could Triple
This $356 million market cap sleep apnea company is betting it can triple its market cap. If history is any guide, it will return nearly 30% a year.
Itamar Medical Acquires Technology and Assets of Spry Health
CAESAREA, Israel, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced that...
Itamar Medical Announces Additional 16 Million Covered Lives for WatchPAT™, the Only Single-Use Sleep Apnea Test that Meets Guidelines
Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois,...
Itamar Medical Comments on U.S. Centers for Medicare & Medicaid Services (CMS) 2021 Fee Schedule with Reimbursement Update for Home Sleep Apnea Testing
WatchPAT™ to effectively maintain current reimbursement levels despite broader reduction in conversion rates WatchPAT™ to effectively maintain current reimbursement levels despite broader reduction in conversion rates
Itamar Medical Announces Results from Multi-Center Study Validate Use of WatchPAT™ in Diagnosing Sleep Apnea in Patients with AFib
Results Further Support Use of WatchPAT for Home-Based Sleep Apnea Testing as an Effective Alternative to In-Lab PSG Testing Results Further Support Use of WatchPAT for Home-Based Sleep Apnea Testing as an Effective Alternative to In-Lab PSG Testing
Source: https://incomestatements.info
Category: Stock Reports